Mylan Can Focus on New Generics After EpiPen Medicaid Settlement

Valeant CEO Confident Divestitures Can Successfully Pare Debt, Skeptics Remain

Valeant CEO Joe Papa Has Been Able to Pay Down Debt, Jim Cramer Explains

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Closing Bell: Teva Tumbles and Trump Disbands CEO Councils

Teva Stock Tumbles Again, Citi Downgrades, Says 'We Have Been Wrong'

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'